nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefuroxime—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Cefuroxime—Agitation—Teniposide—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Cefuroxime—Chills—Fludarabine—lymphatic system cancer	0.00451	0.00451	CcSEcCtD
Cefuroxime—Leukopenia—Teniposide—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Cefuroxime—Pancytopenia—Bleomycin—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Cefuroxime—Liver disorder—Methotrexate—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Cefuroxime—Chest pain—Teniposide—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Cefuroxime—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Cefuroxime—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Cefuroxime—Agitation—Fludarabine—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Cefuroxime—Stomatitis—Bleomycin—lymphatic system cancer	0.004	0.004	CcSEcCtD
Cefuroxime—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Cefuroxime—Tachycardia—Teniposide—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Cefuroxime—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Cefuroxime—Leukopenia—Fludarabine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Cefuroxime—Pruritus—Mechlorethamine—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Cefuroxime—Anorexia—Teniposide—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Cefuroxime—Cough—Fludarabine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Cefuroxime—Pancytopenia—Carmustine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Cefuroxime—Convulsion—Fludarabine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Cefuroxime—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Cefuroxime—Neutropenia—Carmustine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Cefuroxime—Arthralgia—Fludarabine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Cefuroxime—Haemoglobin—Bleomycin—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Cefuroxime—Haemorrhage—Bleomycin—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Cefuroxime—Pancytopenia—Vincristine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Cefuroxime—Dyspnoea—Teniposide—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Cefuroxime—Dysuria—Vincristine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Cefuroxime—Neutropenia—Vincristine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Cefuroxime—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Cefuroxime—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Cefuroxime—Decreased appetite—Teniposide—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Cefuroxime—Renal failure—Carmustine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Cefuroxime—Vomiting—Mechlorethamine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Cefuroxime—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Cefuroxime—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Cefuroxime—Stomatitis—Carmustine—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Cefuroxime—Urinary tract infection—Carmustine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Cefuroxime—Rash—Mechlorethamine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Cefuroxime—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Cefuroxime—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Cefuroxime—Anorexia—Fludarabine—lymphatic system cancer	0.0034	0.0034	CcSEcCtD
Cefuroxime—Stomatitis—Vincristine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Cefuroxime—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Cefuroxime—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Cefuroxime—Chills—Bleomycin—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Cefuroxime—Sweating—Vincristine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Cefuroxime—Renal failure—Mitoxantrone—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Cefuroxime—Nausea—Mechlorethamine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Cefuroxime—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Cefuroxime—Jaundice—Mitoxantrone—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Cefuroxime—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Cefuroxime—Haemoglobin—Carmustine—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Cefuroxime—Urticaria—Teniposide—lymphatic system cancer	0.00323	0.00323	CcSEcCtD
Cefuroxime—Haemorrhage—Carmustine—lymphatic system cancer	0.00322	0.00322	CcSEcCtD
Cefuroxime—Abdominal pain—Teniposide—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Cefuroxime—Body temperature increased—Teniposide—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Cefuroxime—Erythema—Bleomycin—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Cefuroxime—Sweating—Mitoxantrone—lymphatic system cancer	0.00319	0.00319	CcSEcCtD
Cefuroxime—Dyspnoea—Fludarabine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Cefuroxime—Dyspepsia—Fludarabine—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Cefuroxime—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Cefuroxime—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Cefuroxime—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Cefuroxime—Decreased appetite—Fludarabine—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Cefuroxime—Pain—Fludarabine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Cefuroxime—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Cefuroxime—Urethral disorder—Vincristine—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Cefuroxime—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Cefuroxime—Hypersensitivity—Teniposide—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Cefuroxime—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Cefuroxime—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Cefuroxime—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Cefuroxime—Pruritus—Teniposide—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Cefuroxime—Leukopenia—Bleomycin—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Cefuroxime—Body temperature increased—Fludarabine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Cefuroxime—Vaginal infection—Methotrexate—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Cefuroxime—Erythema—Carmustine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Cefuroxime—Cough—Bleomycin—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Cefuroxime—Angiopathy—Vincristine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Cefuroxime—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Cefuroxime—Diarrhoea—Teniposide—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Cefuroxime—Chest pain—Bleomycin—lymphatic system cancer	0.00273	0.00273	CcSEcCtD
Cefuroxime—Chills—Mitoxantrone—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Cefuroxime—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Cefuroxime—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Cefuroxime—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Cefuroxime—Erythema—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Cefuroxime—Vomiting—Teniposide—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Cefuroxime—Agitation—Carmustine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Cefuroxime—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Cefuroxime—Rash—Teniposide—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Cefuroxime—Dermatitis—Teniposide—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Cefuroxime—Headache—Teniposide—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Cefuroxime—Pruritus—Fludarabine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Cefuroxime—Leukopenia—Carmustine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Cefuroxime—Anorexia—Bleomycin—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Cefuroxime—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Cefuroxime—Agitation—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Cefuroxime—Diarrhoea—Fludarabine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Cefuroxime—Convulsion—Carmustine—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Cefuroxime—Nausea—Teniposide—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Cefuroxime—Leukopenia—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Cefuroxime—Chest pain—Carmustine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Cefuroxime—Dyspnoea—Bleomycin—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Cefuroxime—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Cefuroxime—Convulsion—Vincristine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Cefuroxime—Decreased appetite—Bleomycin—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Cefuroxime—Cough—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Cefuroxime—Vomiting—Fludarabine—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Cefuroxime—Convulsion—Mitoxantrone—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Cefuroxime—Rash—Fludarabine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Cefuroxime—Dermatitis—Fludarabine—lymphatic system cancer	0.00225	0.00225	CcSEcCtD
Cefuroxime—Pain—Bleomycin—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Cefuroxime—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Cefuroxime—Headache—Fludarabine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Cefuroxime—Tachycardia—Carmustine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Cefuroxime—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Cefuroxime—Chest pain—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Cefuroxime—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Cefuroxime—Anorexia—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Cefuroxime—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Cefuroxime—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Cefuroxime—Nausea—Fludarabine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Cefuroxime—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Cefuroxime—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Cefuroxime—Urticaria—Bleomycin—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Cefuroxime—Anorexia—Vincristine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Cefuroxime—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Cefuroxime—Body temperature increased—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Cefuroxime—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Cefuroxime—Irritability—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Cefuroxime—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Cefuroxime—Dyspnoea—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Cefuroxime—Somnolence—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Cefuroxime—Anorexia—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Cefuroxime—Decreased appetite—Carmustine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Cefuroxime—Pain—Carmustine—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Cefuroxime—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Cefuroxime—Decreased appetite—Vincristine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Cefuroxime—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Cefuroxime—Somnolence—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Cefuroxime—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Cefuroxime—Pain—Vincristine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Cefuroxime—Pruritus—Bleomycin—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Cefuroxime—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Cefuroxime—Eosinophilia—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Cefuroxime—Pain—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Cefuroxime—Abdominal pain—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Cefuroxime—Body temperature increased—Carmustine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Cefuroxime—Pancytopenia—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Cefuroxime—Dysuria—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Cefuroxime—Neutropenia—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Cefuroxime—Body temperature increased—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Cefuroxime—Abdominal pain—Vincristine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Cefuroxime—Urticaria—Mitoxantrone—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Cefuroxime—Hypersensitivity—Carmustine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Cefuroxime—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Cefuroxime—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Cefuroxime—Vomiting—Bleomycin—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Cefuroxime—Infestation NOS—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Cefuroxime—Infestation—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Cefuroxime—Drowsiness—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Cefuroxime—Rash—Bleomycin—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Cefuroxime—Dermatitis—Bleomycin—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Cefuroxime—Renal failure—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Cefuroxime—Stomatitis—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Cefuroxime—Hypersensitivity—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Cefuroxime—Sweating—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Cefuroxime—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Cefuroxime—Diarrhoea—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Cefuroxime—Nausea—Bleomycin—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Cefuroxime—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Cefuroxime—Dizziness—Carmustine—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Cefuroxime—Haemoglobin—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Cefuroxime—Diarrhoea—Vincristine—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Haemorrhage—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Hepatitis—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Cefuroxime—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Cefuroxime—Urethral disorder—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Cefuroxime—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Cefuroxime—Vomiting—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Cefuroxime—Dizziness—Vincristine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Cefuroxime—Rash—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Cefuroxime—Dermatitis—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Cefuroxime—Headache—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Cefuroxime—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Cefuroxime—Vomiting—Vincristine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Cefuroxime—Rash—Vincristine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Cefuroxime—Dermatitis—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Cefuroxime—Headache—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Cefuroxime—Nausea—Carmustine—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Cefuroxime—Angiopathy—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Cefuroxime—Vomiting—Mitoxantrone—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Cefuroxime—Immune system disorder—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Cefuroxime—Rash—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Cefuroxime—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Cefuroxime—Chills—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Cefuroxime—Headache—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Cefuroxime—Erythema—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Cefuroxime—Nausea—Vincristine—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Cefuroxime—Nausea—Mitoxantrone—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Cefuroxime—Leukopenia—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Cefuroxime—Cough—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Cefuroxime—Convulsion—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Cefuroxime—Arthralgia—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Cefuroxime—Chest pain—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Cefuroxime—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Cefuroxime—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Cefuroxime—Skin disorder—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Cefuroxime—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Cefuroxime—Anorexia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000965	0.000965	CcSEcCtD
Cefuroxime—Dyspnoea—Methotrexate—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Cefuroxime—Somnolence—Methotrexate—lymphatic system cancer	0.000941	0.000941	CcSEcCtD
Cefuroxime—Dyspepsia—Methotrexate—lymphatic system cancer	0.000932	0.000932	CcSEcCtD
Cefuroxime—Decreased appetite—Methotrexate—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000914	0.000914	CcSEcCtD
Cefuroxime—Pain—Methotrexate—lymphatic system cancer	0.000905	0.000905	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000866	0.000866	CcSEcCtD
Cefuroxime—Urticaria—Methotrexate—lymphatic system cancer	0.000841	0.000841	CcSEcCtD
Cefuroxime—Abdominal pain—Methotrexate—lymphatic system cancer	0.000837	0.000837	CcSEcCtD
Cefuroxime—Body temperature increased—Methotrexate—lymphatic system cancer	0.000837	0.000837	CcSEcCtD
Cefuroxime—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00078	0.00078	CcSEcCtD
Cefuroxime—Pruritus—Methotrexate—lymphatic system cancer	0.000749	0.000749	CcSEcCtD
Cefuroxime—Diarrhoea—Methotrexate—lymphatic system cancer	0.000724	0.000724	CcSEcCtD
Cefuroxime—Dizziness—Methotrexate—lymphatic system cancer	0.0007	0.0007	CcSEcCtD
Cefuroxime—Vomiting—Methotrexate—lymphatic system cancer	0.000673	0.000673	CcSEcCtD
Cefuroxime—Rash—Methotrexate—lymphatic system cancer	0.000668	0.000668	CcSEcCtD
Cefuroxime—Dermatitis—Methotrexate—lymphatic system cancer	0.000667	0.000667	CcSEcCtD
Cefuroxime—Headache—Methotrexate—lymphatic system cancer	0.000663	0.000663	CcSEcCtD
Cefuroxime—Nausea—Methotrexate—lymphatic system cancer	0.000629	0.000629	CcSEcCtD
